Boltz
Open protein and small-molecule foundation models for drug discovery (MIT spinout)
Boltz (London, United Kingdom) — open protein and small-molecule foundation models for drug discovery (MIT spinout). On November 19, 2026 it announced a $110M Series A, led by Bessemer Venture Partners. Total raised $138M after a $28M seed. Partnerships with six of the top-20 pharmas (Pfizer, GSK, Takeda, BMS named). Some coverage dates it Nov 18; one outlet adds Nvidia as an investor.
AI
📍 London
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Boltz going public?
No. Boltz is private and has not filed to go public. There is no S-1 on file.
What is Boltz's valuation in 2026?
No confirmed valuation is on record for Boltz. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Boltz filed an S-1?
No public S-1 is on file for Boltz.
Who are Boltz's investors?
Boltz's investors include Bessemer Venture Partners, Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, Obvious Ventures, Greycroft and 3 more.
How much has Boltz raised?
Boltz has raised $138M in total across 1 disclosed round, most recently a Series A of $110M in Nov 2026.
Is Boltz publicly traded — can you buy Boltz stock?
No. Boltz is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Boltz on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series A — $110M (Nov 2026) · Lead: Bessemer Venture Partners
Fundraising Status
Series A · $110M · this month
privateTotal raised $138M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $110M | Nov 2026 | Bessemer Venture Partners | — |
Recent Activity
💰Nov 2026 · Tech.eu · funding
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Boltz has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Boltz has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Bessemer Venture Partners · Andreessen Horowitz · Amplify Partners · Zetta Venture Partners · Obvious Ventures · Greycroft · F-Prime Capital · Hummingbird · Benchling
AIAI for drug discovery
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.